Ontario Institute for Cancer Research (oicr)

Propellon Therapeutics Inc.

Ontario Institute for Cancer Search (oicr)

Scynexis, Inc.

Ontario Institute for Cancer Research

Ahmed Mamai

Methvin Benjamin Isaac

Yong Liu

Michael Robert Peel

Rima Al-Awar

Gennady Poda

David Uehling

Brian Wilson

Pandiaraju Subramanian

Babu Joseph

Keqiang Li

Anh My Chau

Carlos Armando Zepeda-Velazquez

Michael Prakesch

Iain Watson

Andrew Zhang

Julia Katheleen Stille

Justin-Alexander Morin

Julia Kathleen Stille

The present application is directed to compounds of Formula I:

Substituted carboxamides as inhibitors of WDR5 protein-protein binding

The present application is directed to compounds of Formula (I): compounds of Formula (II): compounds of Formula (III): and compounds of Formula (IV): compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics. Specifically claimed are: (1) compounds containing reactive functional groups (compound of formula I), compounds containing compounds to be linked together (compound of formula II) and compounds having a reactive functional group/a compound to be linked (compound of formula IV), (2) an antibody-drug conjugate (compound of formula III), wherein the antibody is covalently attached by a linker to one or more drugs, (3) pharmaceutical compositions comprising compounds of Formula (II) or Formula (III), (4) treatment/diagnosis of disease comprising compounds of Formula (II) or Formula (III), and (5) methods of preparing an ADC of Formula III.

Heterocyclic acyl hydrazone linkers, methods and uses thereof

The present application is directed to compounds of Formula (I)-(VIII):  compositions comprising these compounds and their uses, for example as medicaments and/or diagnostics.

Acyl hydrazone linkers, methods and uses thereof

The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction

The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB and/or by degrading BCL6, such as cancer.

Deuterated compounds as inhibitors of the BCL6 BTB domain protein-protein interaction and/or as BCL6 degraders

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners. 

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer. 

Tricyclic inhibitors of the BCL6 BTB domain protein-protein interaction and uses thereof

The present application is directed to compounds of Formula I: compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Growing community of inventors

Mississauga, Canada

Ahmed Mamai